Applications and the Limitations of Real-World Data in Gene Therapy Trials
Karen Ooms, Joint Chief Operating Officer, Quanticate
In the quest to address rare diseases, one of the most complex and crucial areas in healthcare, the industry is constantly in search of innovative approaches. Enter Real World Evidence (RWE) studies, which are changing the clinical trial landscape in a big way. Contrasting with the controlled environment of Randomized Clinical Trials (RCTs), RWD is an integral part of a decentralised trial approach and offers a unique perspective on the effectiveness of Investigational Medicinal Products (IMPs) in diverse, real-world scenarios. This data, often overlooked in traditional research paradigms, provides crucial insights into patient outcomes and treatment effectiveness across various populations, driving a new era of data for researchers, medical professionals, and patients. Furthermore, RWD can reveal how an IMP interacts with other medications, a factor often overlooked in controlled trial settings. In this article, Karen Ooms, Joint Chief Operating Officer at Quanticate, examines the applications and the limitations of real-world data in gene therapy trials.
With an estimated 7,000 rare diseases touching the lives of over 350 million people globally, the challenge is immense. Traditional clinical trials, while valuable, often grapple with the intricacies of such conditions due to limited patient numbers, varied symptomatology, and scarce historical data, leading to protracted drug development timelines. Increasingly, trials are adopting a hybrid model where they utilize a decentralised approach and collect new RWD from wearable devices and other smart technologies, plus tap into existing patient data from registries and other sources, all while still using traditional site data in their submissions.
This is why many organizations are incorporating RWE studies into their trials, drawing on the capability to gather a multitude of RWD sources such as electronic health records, insurance claims, patient registries, and first-hand patient accounts. This isn't just data; it’s a tapestry of human experiences, offering a deeper, multifaceted understanding of these rare conditions.
However, the path to realizing the full potential of gene therapy is fraught with challenges. Gene therapy, which uses genes to treat or prevent diseases at their most fundamental level, is gaining momentum with technological advancements such as CRISPR/Cas9. This innovative approach offers potential cures by directly fixing the genetic abnormalities causing these diseases. The rarity of these conditions means smaller patient populations for clinical trials, a limited understanding of disease progression, and difficulty in defining suitable endpoints. These research pain points have led to the introduction of RWE into gene therapy trials, which signifies a pivotal shift in how researchers and clinicians approach the development and evaluation of new therapies.
The Bright Spots of Real World Data
Imagine being able to connect with patients scattered across the globe, to understand their unique stories and struggles. RWD makes this possible, breaking down barriers and bringing a wealth of diverse experiences into the spotlight. It’s not just about numbers and statistics; it’s about understanding the human side of disease progression and crafting treatments that resonate on a personal level. Real World Data is revolutionizing the way we approach gene therapy trials by offering unique advantages:
Global Patient Access: One of the foremost benefits of RWE studies is the ability to tap into a vast and diverse patient base, far exceeding the scope of centralized clinical trials, allowing for a deeper dive into patient demographics, disease progression, and treatment outcomes. Utilizing RWD enables researchers to connect with international databases and patient registries, which helps in identifying sub-populations that might benefit most from the therapies, as well as understanding the natural history of diseases by overcoming geographical and logistical barriers, thus enriching data sets and enhancing the relevancy of findings.
Streamlining Drug Development: RWE studies are increasingly acknowledged by regulatory bodies for supplementing clinical trial data, including additional safety and efficacy evidence and identifying potential patient groups. This is especially beneficial for rare diseases, streamlining the development, evaluation, and approval of new treatments, thereby hastening access to novel therapies and enhancing post-marketing surveillance, ensuring that any long-term effects or rare side effects are quickly identified and addressed.
Patient-Centric Care and Cost Efficiency: RWE studies foster a more patient-focused approach to treatment and care. By understanding the real-life experiences of patients, healthcare providers can deliver more tailored and effective treatment strategies. Additionally, patients and caregivers are empowered to make informed decisions about their care, based on a broad spectrum of similar patient experiences. The use of wearable devices to gather RWD also improves patient adherence and reduces the need for travel to clinical sites. Conducting traditional clinical trials for rare diseases is typically costly due to extensive recruitment and study durations. RWE studies offer a cost-effective alternative by leveraging existing data, accelerating the research process, and lessening the financial strain on healthcare systems and patients.
Real World Success Stories
The Impact of RWD in Gene Therapy: The application of RWD is particularly significant in the field of gene therapy. Understanding the long-term effects and variability of treatments is critical, and RWD offers longitudinal data that aids in tracking these outcomes and adapting strategies accordingly. For rare genetic disorders, this translates into more individualized and effective treatment approaches, informed by extensive real-world patient experiences. Several gene therapy trials have already benefited from the integration of RWD. For instance, in trials for rare genetic disorders like Cystic Fibrosis and Hemophilia, RWD has been instrumental in understanding the disease's natural history, identifying patient subgroups, and tailoring interventions accordingly. These success stories underscore the potential of RWD to refine, accelerate, and enhance the development and delivery of gene therapies.
Response to Global Challenges: The COVID-19 pandemic highlighted the adaptability of RWD. Strict lockdowns, social distancing and self-isolation meant patients were unable to get to clinical sites. As the world struggled with the virus, RWD provided timely insights into its behavior, treatment responses, and vaccine effectiveness. This underlines the potential of RWD in tackling global health emergencies, offering valuable lessons applicable in the realm of rare diseases. The use of digital technologies helped overcome the challenges set out by the pandemic and have created new trends in the way Clinical Research Organizations (CROs) and pharma/biotech conduct clinical trial analysis.
Advancements in digital data-capturing technology have fundamentally transformed the landscape, steering the market away from conventional paper-based record-keeping. These technological innovations facilitate more patient-focused approaches in study conduct, as Clinical Research Organizations (CROs) and sponsors increasingly utilize these technologies to gather data beyond clinical sites. With the industry trending towards virtual, decentralized, and hybrid trial methodologies, it's crucial for CROs and sponsors to gain a thorough understanding of these approaches, and be well-rehearsed in how to handle RWD, analyse this data type and design RWE trials. There are many sources of RWD such as longitudinal databases, medical records and data from other new device sources, so ensuring proficiency in how to design trials and handle these various data sources is key.
Navigating the Challenges
Admittedly, while the use of RWD is promising, it's not without limitations. There’s the challenge of making sure the stories we gather are accurate and not muddled by other factors. Ensuring the quality and privacy of this data is paramount, akin to protecting the most personal and sensitive aspects of a patient’s life journey. The representativeness can also vary significantly, potentially leading to biases or inaccurate conclusions. The potential for 'dirty data' – data not rigorously checked for inconsistencies or errors – is another issue. With the vast amount of data available, there is also risk of overanalysis, leading to conclusions that may not be supported by the data.
Technological advancements in data analytics, artificial intelligence, and machine learning are revolutionizing how we interpret vast datasets, but as we continue to embrace this wealth of information, it’s crucial to remember that at its core, it’s about people – their experiences, their struggles, and their requirements.
Regulatory acceptance of RWD is rapidly evolving, with authorities scrutinizing the methodologies and validity, and also emphasizing the need for stringent guidelines to ensure its ethical use. This involves clear protocols for data collection, usage, and sharing, ensuring that patient rights and confidentiality are never compromised. To overcome these challenges, stakeholders in the gene therapy field must advocate for standardization in data collection and analysis methods, invest in robust data infrastructure, and foster collaborations between academia, industry, and regulatory bodies.
It’s important to note that the integration of RWD into gene therapy trials doesn’t diminish the significance of traditional randomized, placebo-controlled trials (RCTs). Rather, it provides a complementary perspective, creating a richer, more nuanced understanding of treatments, their impacts on patients with rare diseases, and the application of therapeutic interventions. It's essential to strike a balance between the rigor of RCTs and the expansive insights offered by RWD. This approach allows for a more nuanced and comprehensive evaluation of IMPs, catering to the diverse needs and contexts of patients suffering from rare diseases.
The Road Ahead
As we look to the future, the story of RWD in gene therapy is one of promise and potential. With technological advancements in data collection and analytics, RWD will become even more robust and insightful. It promises to not only enhance the design and execution of gene therapy trials but also ensure that therapies are safe, effective, and tailored to those who need them most. It's not just about embracing new technology or data; it's about reshaping our understanding and approach to treating rare conditions, with each patient's story adding a piece to the puzzle, moving us closer to more effective treatments and improved care.
As we continue to navigate this exciting era of genetic medicine, the journey of incorporating Real World Data into gene therapy trials is a testament to an evolving narrative in medical research and patient care. It represents a shift towards a more inclusive, comprehensive, and patient-centric approach to healthcare, blending the rigor of scientific research with the richness of human experiences. While challenges persist, the potential of RWD to enhance our understanding, optimize gene therapy trials, develop more effective treatments, and improve patient outcomes is immense.
Author Bio
Karen Ooms is a Chartered Fellow of the Royal Statistical Society and has a background in biostatistics spanning over 25 years. Prior to joining Quanticate in 1999 (Statwood), Karen was a Senior Statistician at Unilever.
